Elisa Agostinetto· @ElisaAgostinett · X·· 1 天前评分90
正文 · 原文
At #ESMO26 Proffered Paper 2️⃣ on #breastcancer
@antgiorda presents FOURLIGHT-1
Atirmociclib (CDK4i) + fulvestrant in HR+ aBC after PD to CDK4/6i ⬆️ PFS (delta of 3 months)
Ongoing ph3 trial of atirmociclib in 1 line
@OncoAlert
187 浏览 · 5 赞 · 6 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Elisa Agostinetto · x.com